Verona Pharma plc Verona Pharma Plc: Pdmr Dealing -- Purchase By Chairman

 
TIDMVRP 
 
   LONDON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, announces that Dr. David 
Ebsworth, Chairman of the Company, has notified the Company that he has 
purchased a further 75,000 ordinary shares of 5 pence each in the 
Company ("Ordinary Shares") at a total purchase price of GBP32,500, at 
prices between 42 and 45 pence per Ordinary Share and an average price 
of 43.33 pence. 
 
   Following the purchases, Dr. Ebsworth will have an interest in the 
Company of 370,387 Ordinary Shares, representing 0.35% of the Company's 
issued share capital. 
 
   Further information is provided below in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
   Notification and public disclosure of transactions by persons 
discharging managerial responsibilities and persons closely associated 
with them 
 
 
 
 
1    Details of the person discharging managerial responsibilities/person 
      closely associated 
---  ---------------------------------------------------------------------- 
a)   Name                                       David Ebsworth 
---  -----------------------------------------  --------------------------- 
2    Reason for the notification 
---  ---------------------------------------------------------------------- 
                                                Chairman 
 a)   Position/status 
---  -----------------------------------------  --------------------------- 
b)   Initial notification/Amendment             Initial notification 
---  -----------------------------------------  --------------------------- 
3    Details of the issuer, emission allowance market participant, 
      auction platform, auctioneer or auction monitor 
---  ---------------------------------------------------------------------- 
a)   Name                                       Verona Pharma plc 
---  -----------------------------------------  --------------------------- 
b)   LEI                                        213800EVI6O6J3TIAL06 
---  -----------------------------------------  --------------------------- 
 
 
 
 
 
 
     Details of the transaction(s): section to be repeated 
      for (i) each type of instrument; (ii) each type of 
      transaction; (iii) each date; and (iv) each place 
4     where transactions have been conducted 
---  ------------------------------------------------------------------------- 
     Description of the 
     financial instrument,     Ordinary Shares of 5 
a)   type of instrument        pence each 
     Identification code       GB00BYW2KH80 
---  ------------------------  -------------------------  ---------  --------- 
     Nature of the             David Ebsworth purchased 
b)   transaction               75,000 Ordinary Shares 
 
c)   Price(s) and volume(s)              Date             Price(s)   Volume(s) 
                               -------------------------  ---------  --------- 
      11 November 2019                      42 pence                    25,000 
  -------------------------  --------------------------------------  --------- 
      12 November 2019                      43 pence                    25,000 
  -------------------------  --------------------------------------  --------- 
      13 November 2019                      45 pence                    25,000 
  -------------------------  --------------------------------------  --------- 
d)   Aggregated information    75,000 Ordinary Shares 
 - Aggregated volume       43.33 pence 
 - Price 
 --------------------------------------------------------------      --------- 
e)   Dates of the              As per 4c) above 
      transactions 
---  ------------------------  ------------------------------------  --------- 
f)   Place of the              London Stock Exchange, AIM 
      transactions 
---  ------------------------  ------------------------------------  --------- 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
Victoria Stewart, Director of Communications 
 
N+1 Singer                                         Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell / George Tzimas (Corporate Finance) 
Mia Gardner (Corporate Broking)
(END) Dow Jones Newswires
November 14, 2019 02:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024